Member Info for CauldStream7

Ave Eva, or Hail Eva, as the Romans would have said. This BB will be a lot brighter and more interesting now that you are back.

Yes, Lupuzor was mentioned by Chairman Tim or one of his fellow Board members as a possible therapeutic for Covid 19 patients. It was seen as offering to alleviate inflammation of internal organs such as the lungs. There has been little mention of it in this context since May or so last year.

Dallo

Thanks for your very informative posts in contrast to Nolupus' constant questions about the expiry date of the Lupuzor patent - obviously implying that it would soon expire - but without any evidence.
If the worries of Nolupus on the patent issue were genuine he could produce his evidence - but so far no sign of that.
Nolupus has played the part of Cassandra as long as I can remember and I think his nom-de-plume shows where he stands. He does not really believe that Lupus exists but is rather some type of syndrome with many faces. Hence No- lupus.

This RNS is much more negative for Lupuzor prospects than I could ever have imagined. It's beyond belief that IMM's CEO is "extremely pleased" with the FDA position: no SPA, further info from IMM on the pharma science behind Lupuzor, yet another delay. He needs to explain why he is "extremely pleased" to enlighten shareholders without a degree in pharma science.

There's a traffic jam at the FDA caused by everyone there working on vaccines and therapeutics connected with Covid - 19.
So what update can Avion supply?
Invest in Patience!

Uddin
Thanks for reminding us of the excellent deal that IMM signed with Avion a year ago and of the large financial commitment that Avion ($25million) that made to the new Lupuzor Phase 3 trial. They must have really been convinced by IMM's case and the market potential for Lupuzor.

Uddin 179.

I do not think it is terribly important that our Chairman has stated that IMM is fully funded until 2023. It depends on the requirments of R and D within the company. IMM recently appointed Dr Tim Franklin as Chief Operating Officer. If he is worth his salt he may well wish to push certain of the research lines to accelerate their product becoming marketable. And that might require further funding.
Remember that there were 2 RNS announcements on 30th March and 14th May this year about the various research programmes that IMM is involved in.
30th March: 1. The efficacy of Lupuzor in treatment of CIDP.
2. Research on an Anti-Fungal product BioAMP-B.
3. Research into an Anti-Bacterial IPP20311.
4. A treatment of low sugar events in Diabetes.
On 14th May there was a further RNS which in addition to funding news mentioned two other lines of research
the first the Ureka research on the prevention of Covid-19 virus entering host cells and the other being the use of Lupuzor in the treatment of cytokine flares found in Lupus and. Covid-19 patients.
It would not surprise nor disappoint me if it turned out that it will require more than was in the initial budget to bring one or more of these research activities to a conclusion. And if Dr Franklin is wanting to achieve this surely he will urge the IMM Board to seek further funding. That should be taken as a good sign. Pharma R&D does not come cheap.

At the moment it looks as though the FDA will approve Avion's SPA proposal for the Phase 3 trial. We'll know by Christmas IMO.

I've been struck in recent months by a new, almost jovial, spirit among many contributors to this BB.
Despite or maybe because of the restrictions on our mixing with family and friends it seems to have inspired many of our members to display humour, matiness/friendship and openness about our investing policies with regard to IMM and other shares.
It's been really fun to read many of the posts on this BB - there is teasing but it's not malicious. So keep it coming. It's particularly valued by those having to self isolate during the past eight months.

Best wishes all. May IMM come good this side of Christmas!

Sicilian:
Thanks for quoting these remarks from the FDA.
Facts not guesses. We could wait for a few weeks yet - just as I suggested a few days ago - for approval of Avion's SPA request.

I fear that the FDA is totally caught up in the turmoil over Covid, in particular the struggle between FDA and the Trump administration which wants the normal safety procedures normally required by the FDA before a vaccine is approved to be relaxed. There is a chance that all other drugs being put forward for SPA Phase 3 trials are being put into the pending tray until Nvember 3rd. Only then will the political pressures being heaped on the FDA be reduced and normal work resume for FDA staff.

No news is neither good nor bad - only news.
Speculation on the outcome is for the birds. Too many "known unknowns and unknown unknowns". Patience my friends!

Rebarm
Muller is alive and as influential as ever. Was appointed by Pres Macron 2 or 3 months ago to a committee of 12 to supervise the French Govt's R and D approach to vaccines etc to fight COVID 19 so must have figured in the trial that Ureka is involved in. I'm sure she is keeping a close eye on what happens on Lupuzor both regards the Phase 3 trial and its use as a therapeutic in Covid-19 cases. It's because she is involved that I stick with IMM. Like you and most others I distrust our Chair ever since his ill-advised cheerfulness immediately prior to the disastrous outcome of the previous Lupuzor Phase 3 trial.
As for the FDA consideration of the SPA submitted by Avion, I presume that FDA will have taken the full 45 days to give its reply (ie up until today USA time). Avion and IMM will need time to consider their response before letting us know the result and its consequences for the new Phase 3. Still plenty of buys around - rather more than sells.

Eva
I've held IMM shares since 2013. Have bought them at intervals since then, following the SP up and down. Like you I bought some at the top when the price was close to 180p but most have been bought below 20p in the past year so average down to between 40-50p depending on which account I hold them in.
Such a relief to find someone else nursing losses compared with all the clever people who seem to have bought all their shares when the price was below 15p. Lucky them! I admire their investment skill.

Damned if I can understand how the SP can end the day lower than yesterday's close. So many more buys than sells. The SP heading over 16p by midday and then a steady decline despite the preponderance of buys, ending with a buy of 300k at end of afternoon at shade under 15p.
Can someone please explain?

Perhaps it is because the rest of the market is tanking that IMM 's sp is holding up quite well. Why not invest in a pharma co. with prospects than in oil majors with only negative ones?

Dallo. Thanks for this post. If only wish I had taken your advice to derisk before the first Phase 3 trial flopped. If only - the perennial moan of the over-greedy/optimistic investor that I was 3 years ago.
I hope there will be a next time and I hope it will not end in tears.

Dallo; Thanks for your informative posts.
The patients from Mauritius are a red herring. In the first Phase 3 trial they were part of the European cohort which showed a statistically significant positive result amongst the Lupus antibody positive group.
The failure of the previous Phase 3 was caused by the USA group which too small and which showed a strange result; the lupus antibody positive patients responded better to the Standard of Care (SOC) drugs plus placebo than the patients who were on SOC plus Lupuzor. But the number of patients was too small - just in single figure groups of Lupus positive patients. The European cohort was much larger and was almost certainly better selected.
So imo the key to success in the new Phase 3 trial will be the American cohort - the number of patients and the care in their selection, added to the best US specialist advice on selection procedures . I think that Zimmer and Muller will indeed take good care again with the European cohort.

Nolupus.
I wish I could answer but I can't. There are too many "known unknowns" and "unknown unknowns" to be able to predict what will be the outcome for IMM's drug programmes certainly as long as the Covid 19 pandemic continues.
I had believed that by the end of this year we would have received notification that the Lupuzor Phase 3 trial would have made progress and that at the very least the recruitment of patients for the trial would have been under way. But now we don't even know if the FDA has approved the parameters for the new Phase 3 trial. Is the FDA able to evaluate any new drug trials if they are not directly related to dealing with Covid 19 either as a vaccine or as a therapeutic?
The only trial of an IMM drug that we know for certain is taking place is in the trial supported by the French Govt in which the IMM subsidiary, Ureka, is taking part. It's pretty sophistated research and it's anyone's guess how long it will take to come up with a drug delivery system which will halt or slow the Virus.
It is for these reasons that we need either the Chairman or the CEO to issue regular RNS notices to shareholders, not to puff the shares, which is not allowed under AIM rules, but to keep shareholders informed as to what effects the Covid 19 virus is having on IMM's research programmes. For all we know they have been postponed with research lab workers being reassigned to other more urgent tasks in relation to bringing an end to the pandemic.
We should be kept informed.
So sorry Nolupus not to give you answers but only to add to your questions.

You should be prepared to be disappointed. The IMM research programmes are not 100m sprints but 5000m medium distance efforts. If we don't get a RNS this month it may be November/December before we receive any substantial news. In August, ll of France goes on vacation and that is where IMM's research work is done. Allow September for researchers to get their get used to their microscopes again and October to arrive perhaps at some interim endpoints. Maybe some results by November/December.
I hope my pessimism is unfounded and that we'll get (good?) news before then, but I feel doubtful.

Nlp and others; what's happened to the crystal ball that indicated good news this week?
A malfunction?
What makes you all so expectant that news is about to burst forth?
If you read again the licence agreement between IMM and Avion, there is only an intention to begin the Phase 3 trial in 2020 following agreement with FDA on its design. Since we're far from the end of 2020 the long -awaited news could still be several months off.
I hope not, but better to be surprised on the upside than continuing to fret week by week.